The primary objective of this study is to evaluate the safety and tolerability of JAB-21822 monotherapy to determine the MTD and PR2D during Dose Escalation phase; then to evaluate preliminary antitumor activity when JAB-21822 administered alone and combination with cetuximab during Dose Expansion phase in adult participants with advanced solid tumors harboring KRAS G12C mutation.

Arm A0&A1: JAB-21822 Monotherapy
Arm B: JAB-21822 combination with Cetuximab in mCRC patients

Inclusion Criteria:

Participants must be able to provide an archived tumor sample
Histologically or cytologically confirmed solid tumors with KRAS G12C mutation
Must have received at least 1 prior standard therapy
Must have at least 1 measurable lesion per RECIST v1.1
Must have adequate organ function
Must be able to swallow and retain orally administered medication

Locations
United States, Arizona
Mayo Clinc 
Phoenix, Arizona, United States, 85054
Mayo Clinc 
Scottsdale, Arizona, United States, 85259
United States, Florida
Mayo Clinc 
Jacksonville, Florida, United States, 32224
United States, Utah
University of Utah 
Salt Lake City, Utah, United States, 84112

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05002270